Defence Therapeutics Inc.
DTCFF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $27,899 | $39,666 | $112,380 | $70,589 |
| - Cash | $905 | $57 | $2,793 | $507 |
| + Debt | $1,105 | $1,746 | $1,746 | $0 |
| Enterprise Value | $28,099 | $41,355 | $111,333 | $70,082 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$53 | $0 | -$14 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,297 | -$12,676 | -$6,481 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$2,587 | -$13,193 | -$6,763 | -$7,344 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.052 | -0.3 | -0.17 | -0.2 |
| % Growth | 82.7% | -76.5% | 15% | – |
| Operating Cash Flow | -$2,497 | -$4,288 | -$7,657 | -$6,044 |
| Capital Expenditures | $0 | -$203 | -$66 | $0 |
| Free Cash Flow | -$2,497 | -$4,492 | -$7,723 | -$6,044 |